A Sharply Defined Pattern of Central Retinal Thinning
Imagine a single, precisely cut-out patch fading from the centre of an otherwise even, fully lit photograph, while everything around that patch stays exactly as bright as before. That is roughly how central areolar choroidal dystrophy behaves on a retinal examination — a sharply defined zone of atrophy sitting directly beneath the macula, with the surrounding retina and choroid remaining largely untouched. That crisp, clean boundary, rather than a gradually fading edge, is one of the condition's more recognisable features.
Most Ghanaian patients we see with this condition are in their thirties or forties, and the story is usually similar: a routine eye check turned up a pale, oddly precise patch that didn't sit right with what an ophthalmologist would expect from ordinary age-related change at that stage of life, prompting a referral for a closer look.
Patients describe the change less as a sudden event and more as something they only notice in hindsight — small print that has quietly become harder to make out over two or three years, or a habit of turning slightly to bring a face into clearer view off to one side. A distinct dark or grey patch settles into the very centre of vision as the disease advances, sharply bordered rather than fading gradually at its edges. Everyday orientation, walking through a crowded market or finding a doorway, stays unaffected, since it is only the small, central window of vision that the disease touches — dim-light vision in particular is left alone by this condition.
The PRPH2 gene sits behind most confirmed cases, coding for a structural protein that photoreceptor cells depend on to hold their shape and function properly. When it fails, three tightly connected layers beneath the macula — the choriocapillaris, the retinal pigment epithelium, and the photoreceptors resting above them — break down together as a unit, but strictly within that one confined region rather than spreading elsewhere across the retina. Families typically see the condition passed down in an autosomal dominant fashion, appearing in generation after generation.
On examination, the atrophic zone stands out with an unusually crisp, almost geometric edge, and fundus autofluorescence imaging is what lets us trace that boundary with real precision. OCT is used alongside it to check how intact the photoreceptor layer remains right at the rim of the patch — often the part of the retina that matters most for planning ahead. One detail that regularly reassures both patient and specialist is a near-normal electroretinogram result, since it confirms the disease process has stayed local rather than spreading more broadly, and PRPH2 genetic testing then closes out the diagnostic picture.
Rather than a fixed protocol, care here is paced to match how quickly the atrophic zone is actually growing, which our team establishes through imaging done at intervals rather than a single visit. Eligible patients are considered for regenerative stem cell therapy with the specific goal of supporting retina that still functions around the edges of the affected area, and as the central blind spot becomes more established, we work with the patient on practical low-vision strategies suited to their particular pattern of loss.
Not at all — it actually fits the diagnosis rather than contradicting it. Because this condition targets a small central zone and leaves the rod cells responsible for night vision untouched, driving after dark tends to remain genuinely unaffected even as reading and face recognition become harder.
It doesn't really follow a fixed timeline — a few patients stay nearly unchanged across a decade of monitoring, while others see clearer progression within a few years. That unpredictability is exactly why we schedule imaging at set intervals rather than assuming any single growth rate applies.
The two can look alike under examination, but they're driven by different causes and arrive at very different points in life — yours by an inherited gene fault showing up decades earlier, hers by age-related changes accumulating much later. Confirming which is which comes down to genetic testing and the age things began.
For the great majority of patients, no — mobility, orientation, and awareness of your surroundings stay reliable throughout, because the disease keeps to a defined central area rather than reaching into the wider visual field that guides everyday movement.